Open AccessCutaneous Toxicity After Chemoradiotherapy and PD‐L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye
Author(s) -
Ende Tom,
Menting Stef P.,
Ambarus Carmen A.,
Oijen Martijn G.H.,
Laarhoven Hanneke W.M.
Publication year - 2019
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2018-0674
Subject(s) - medicine , atezolizumab , carboplatin , paclitaxel , oncology , adverse effect , chemotherapy , chemoradiotherapy , radiation therapy , immunotherapy , adenocarcinoma , esophageal cancer , pembrolizumab , cisplatin , cancer
Dermatological adverse events have frequently been reported after immune checkpoint inhibition. When an adverse event occurs during combination of immune checkpoint inhibition with chemotherapy, the question arises which agent is responsible. Unnecessary withdrawal of either chemotherapy or immunotherapy could lead to suboptimal treatment outcomes. Here we report on two patients who developed a cutaneous drug reaction with fever during treatment with paclitaxel, carboplatin, radiotherapy, and PD‐L1 inhibition (atezolizumab) for resectable esophageal adenocarcinoma. In the first case atezolizumab was suspected, and in the second paclitaxel. We discuss the clinical manifestation, treatment, and pathophysiology underlying both cases.